Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder

@article{Coric2010MulticenterRD,
  title={Multicenter, randomized, double‐blind, active comparator and placebo‐controlled trial of a corticotropin‐releasing factor receptor‐1 antagonist in generalized anxiety disorder},
  author={Vladimir Coric and Howard H Feldman and Dan A. Oren and A. Shekhar and Joseph A Pultz and Randy C. Dockens and Xiaolin Wu and Kimberly A Gentile and Shu-Pang Huang and Eileen Sproat Emison and Terrye A. Delmonte and B.B. D’Souza and Dan L. Zimbroff and Jack A. Grebb and Andrew W. Goddard and Elyse G Stock},
  journal={Depression and Anxiety},
  year={2010},
  volume={27}
}
Background: Antagonism of corticotropin‐releasing factor (CRF) receptors has been hypothesized as a potential target for the development of novel anxiolytics. This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF‐1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD). Method: This was a multicenter, randomized, double‐blind, placebo‐controlled and active comparator trial. Two hundred and sixty patients were randomly assigned to… 
Pexacerfont as a CRF1 antagonist for the treatment of withdrawal symptoms in men with heroin/methamphetamine dependence: a randomized, double-blind, placebo-controlled clinical trial
TLDR
The findings favor pexacerfont as a potential treatment for withdrawal from drug dependence; however, further comprehensive studies are warranted.
Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436
TLDR
ABT-436 regimens of 200–800 mg once daily (QD) for 7 days attenuated basal HPA axis activity and support further evaluation of ABT- 436 for treatment of disorders in which HPAaxis dysregulation may have an etiologic role.
Preliminary evidence of anxiolytic effects of the CRF1 receptor antagonist R317573 in the 7.5% CO2 proof-of-concept experimental model of human anxiety
TLDR
It is shown that a drug that acts to inhibit the CRF1 receptor shows efficacy in the 7.5% CO2 model of anxiety in healthy participants and is comparable with those effective in preclinical models.
The Corticotropin Releasing Hormone-1 (CRH1) Receptor Antagonist Pexacerfont in Alcohol Dependence: A Randomized Controlled Experimental Medicine Study
TLDR
Pexacerfont treatment had no effect on alcohol craving, emotional responses, or anxiety, and there was no effect of pexacerfont on neural responses to alcohol-related or affective stimuli, despite drug levels in CSF that predict close to 90% central CRH1 receptor occupancy.
Meta-analysis: Risk of dry mouth with second generation antidepressants
Comparative Remission Rates and Tolerability of Drugs for Generalised Anxiety Disorder: A Systematic Review and Network Meta-analysis of Double-Blind Randomized Controlled Trials
TLDR
Only agomelatine manifested better remission with relatively good tolerability, however, the others were worse than placebo in terms of tolerability but these results were limited by small sample sizes.
The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects
TLDR
The findings provide the first translational evidence that CRF1 antagonists with slow receptor dissociation kinetics may have increased efficacy to dampen HPA axis responses and reduce stress-induced alcohol craving in alcohol-dependent patients.
Meta-analysis: Second generation antidepressants and headache.
Meta-Analysis of Placebo Response in Adult Antidepressant Trials
TLDR
Magnitude of placebo symptom improvement differed significantly based on diagnostic indication with improvement being significantly less in obsessive-compulsive disorder than anxiety and depression.
A selective, non-peptide CRF receptor 1 antagonist prevents sodium lactate-induced acute panic-like responses.
TLDR
The data suggest that selective CRF1 receptor antagonists could be a novel target for developing anti-panic drugs that are as effective as benzodiazepines in acute treatment of a panic attack without the deleterious side-effects (e.g. sedation and cognitive impairment) associated with benzodiazines.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression.
TLDR
Although CP-316,311 was safe and well tolerated in this study population, it failed to demonstrate efficacy in the treatment of major depression and the trial was terminated.
High-Affinity CRF1 Receptor Antagonist NBI-34041: Preclinical and Clinical Data Suggest Safety and Efficacy in Attenuating Elevated Stress Response
TLDR
It is suggested that NBI-34041 is safe and does not impair basal regulation of the HPA system but improves resistance against psychosocial stress and demonstrates that inhibition of the CRF system is a promising target for drug development against depression and anxiety disorders.
Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets.
TLDR
If it is confirmed that the CRF(2) receptor contributes importantly to anxiety and depression, the development of small moleculeCRF(1) receptor antagonists would be therapeutically useful and developed as novel treatments for affective and stress disorders.
Corticotrophin Releasing Factor-Induced Synaptic Plasticity in the Amygdala Translates Stress into Emotional Disorders
TLDR
Results show for the first time a stress peptide-induced behavioral syndrome that can be correlated with cellular mechanisms of neural plasticity, a novel mechanism that may explain the etiological role of stress in several chronic psychiatric and medical disorders.
Innovative Approaches for the Treatment of Depression: Targeting the HPA Axis
TLDR
Agents that intervene with the mechanisms involved in (dys)regulation of cortisol synthesis and release are under investigation as possible therapeutic agents.
Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety
  • M. Keck
  • Medicine, Psychology
    Amino Acids
  • 2006
TLDR
The cumulative evidence makes a strong case implicating dysfunction of genes involved in regulation of corticotropin releasing factor and vasopressin in the etiology and pathogenesis of depression and pathological anxiety.
Stress and central Urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor.
...
1
2
3
4
5
...